We are live on ! Find out more
CYAD

Celyad Oncology SA American Depositary Shares
CYAD

Delisted

CYAD was delisted on the 18th of May, 2023.

Back to rankings

8 hedge funds and large institutions have $11.4M invested in Celyad Oncology SA American Depositary Shares in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 8 → 8 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

32% less capital invested

Capital invested by funds: $16.8M → $11.4M (-$5.41M)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
8
Holders Change
–
Holders Change %
0%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CS
Credit Suisse
Switzerland
+$1.68K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$35K
2
Wells Fargo
Wells Fargo
California
-$7.5K
3
HF
HRT Financial
New York
-$7.03K
4
Morgan Stanley
Morgan Stanley
New York
-$200
5
UBS Group
UBS Group
Switzerland
-$12

CYAD Hedge Fund Activity: Q2 2022 in Review

8 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q2 2022, worth a combined $11.4M — down 32% from $16.8M a quarter earlier.

Fund positioning in CYAD was balanced in Q2 2022: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 4 trimmed.

The largest buyer was Credit Suisse, opening a new position worth an estimated $1.68K. The largest seller was Citadel Advisors, exiting entirely with an estimated $35K sold.

  • 8 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $11.4M of Celyad Oncology SA American Depositary Shares stock for Q2 2022, down 32% quarter-over-quarter.
  • 1 fund opened new Celyad Oncology SA American Depositary Shares positions in Q2 2022 and 1 closed out, a net change of 0 holders.
  • The largest Celyad Oncology SA American Depositary Shares buyer in Q2 2022 was Credit Suisse, an estimated $1.68K added.
  • The largest Celyad Oncology SA American Depositary Shares seller in Q2 2022 was Citadel Advisors, an estimated $35K sold.

Based on aggregated 13F filings for Q2 2022.